<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01804205</url>
  </required_header>
  <id_info>
    <org_study_id>MgRoc 60</org_study_id>
    <nct_id>NCT01804205</nct_id>
  </id_info>
  <brief_title>Magnesium Sulphate and Rocuronium in Patients Over 60</brief_title>
  <official_title>Effects of Magnesium Sulphate on the Pharmacodynamics of Rocuronium in Patients 60 Years or Older: Randomised and Double-Blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pedro Rotava</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Nacional de Cancer, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Nacional de Cancer, Brazil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of MgSO4 administration on the
      pharmacodynamics of rocuronium in patients with 60 or more years of age.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total recovery time of neuromuscular block (DurTOF0.9)</measure>
    <time_frame>Within the surgical procedure</time_frame>
    <description>Time from the start of injection of rocuronium until TOF ratio 0.9</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Onset time</measure>
    <time_frame>Within the surgical procedure</time_frame>
    <description>Time from the start of injection of rocuronium until 95% depression of the first twitch (T1) of the TOF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical duration (Dur25%)</measure>
    <time_frame>Within the surgical procedure</time_frame>
    <description>Time from the start of injection of rocuronium until T1 of the TOF had recovered to 25% of the initial T1 value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery index (Dur25-75%)</measure>
    <time_frame>Within the surgical procedure</time_frame>
    <description>Time between 25% and 75% recovery of the initial T1 value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery time (Dur25%TOF0.9)</measure>
    <time_frame>Within the surgical procedure</time_frame>
    <description>Time between 25% recovery of the initial T1 value and a TOF ratio of 0.9</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Magnesium sulfate group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the magnesium group, patients received MgSO4 30 mg/kg in 0.9% physiological saline (total volume 100 ml) intravenously, for 10 min, and then continuous intravenous infusion of MgSO4 at a rate of 1 g/h during the surgical procedure until the maximum of 3 h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Controls received 100 ml of 0.9% physiological saline, for 10 min, and then continuous intravenous infusion of saline at a rate of 33 ml/h during the surgical procedure until the maximum of 3 h.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Sulfate</intervention_name>
    <description>MgSO4 30 mg/kg in 0.9% physiological saline (total volume 100 ml) intravenously, for 10 min, and then continuous intravenous infusion of MgSO4 at a rate of 1 g/h during the surgical procedure until the maximum of 3 h</description>
    <arm_group_label>Magnesium sulfate group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>100 ml of 0.9% physiological saline, for 10 min, and then continuous intravenous infusion of saline at a rate of 33 ml/h during the surgical procedure until the maximum of 3 h</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  60 years or older

          -  ASA physical status I-III

          -  Scheduled for elective oncologic head and neck surgery

        Exclusion Criteria:

          -  Severe renal insufficiency (calculated creatinine clearance &lt; 30 ml/min)

          -  Pre-operatory serum magnesium values &gt; 2.5 mEq/l

          -  Patients receiving medications known to affect neuromuscular function (furosemide,
             aminoglycoside, anticonvulsivants, calcio channel blocker, litium, azatioprine,
             cyclofosfamide)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro Rotava, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Cancer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Nacional de Câncer</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20230130</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Kussman B, Shorten G, Uppington J, Comunale ME. Administration of magnesium sulphate before rocuronium: effects on speed of onset and duration of neuromuscular block. Br J Anaesth. 1997 Jul;79(1):122-4.</citation>
    <PMID>9301400</PMID>
  </reference>
  <reference>
    <citation>Czarnetzki C, Lysakowski C, Elia N, Tramèr MR. Time course of rocuronium-induced neuromuscular block after pre-treatment with magnesium sulphate: a randomised study. Acta Anaesthesiol Scand. 2010 Mar;54(3):299-306. doi: 10.1111/j.1399-6576.2009.02160.x. Epub 2009 Nov 16.</citation>
    <PMID>19919585</PMID>
  </reference>
  <reference>
    <citation>Fuchs-Buder T, Claudius C, Skovgaard LT, Eriksson LI, Mirakhur RK, Viby-Mogensen J; 8th International Neuromuscular Meeting. Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision. Acta Anaesthesiol Scand. 2007 Aug;51(7):789-808.</citation>
    <PMID>17635389</PMID>
  </reference>
  <reference>
    <citation>Dubois PE, Gourdin M, Jamart J, Broka SM, Eucher P, D'Hollander A. Early and late parameters describing the offset of neuromuscular blockade are highly intercorrelated. Acta Anaesthesiol Scand. 2012 Jan;56(1):76-82. doi: 10.1111/j.1399-6576.2011.02596.x.</citation>
    <PMID>22150409</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2013</study_first_submitted>
  <study_first_submitted_qc>March 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2013</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Cancer, Brazil</investigator_affiliation>
    <investigator_full_name>Pedro Rotava</investigator_full_name>
    <investigator_title>Mr</investigator_title>
  </responsible_party>
  <keyword>magnesium sulfate</keyword>
  <keyword>rocuronium</keyword>
  <keyword>neuromuscular block</keyword>
  <keyword>onset time</keyword>
  <keyword>elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rocuronium</mesh_term>
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

